|
Antibody specificity / reagent / analyte |
Ig |
Substrate |
Species |
Format
|
EI 2650-9601 A |
Varicella zoster virus |
IgA |
|
semi-quantitative |
96 x 01 |
EI 2650-9601 G |
Varicella zoster virus (VZV) |
IgG |
10/100/500/5000 IU/I |
96 x 01 | |
EI 2650-9601 M | Varicella zoster virus (VZV) incl. IgG/RF absorbent |
IgM |
semi-quantitative |
96 x 01 | |
EI 2650-9601-1 G | Varicella zoster virus (VZV) avidity determination |
IgG |
10/100/500/5000 IU/I |
96 x 01 | |
EI 2650-9601-2 M | Varicella zoster virus (VZV) glycoprotein incl. IgG/RF absorbent |
IgM | semi-quantitative | 96 x 01 | |
EI 2650-9601-L A | Varicella zoster virus (VZV) antibody determination in CSF |
IgA | 5/25/50/100 U | 96 x 01 | |
EI 2650-9601-L G | Varicella zoster virus (VZV) antibody determination in CSF |
IgG | 5/25/50/100/175/230 U | 96 x 01 | |
DN 2410-1601-11 G DN 2410-6401-11 G |
"TO.R.C.H. 10" (Toxoplasma gondii, Rubella virus, CMV, HSV-1, HSV-2, Bordetella pertussis, Chlamydia trachomatis, Parvovirus B19, Treponema pallidum, VZV separately) |
IgG |
EUROLINE | 16 strips 64 strips |
|
FI 2650-1005 A FI 2650-1010 A FI 2650-1005 G FI 2650-1010 G FI 2650-1005 M FI 2650-1010 M FI 2650-1005 X FK 2650-1005 |
Varicella zoster virus (VZV |
IgA IgG IgM avidity test |
infected cells |
EU 168 |
10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system) 10 x 05 (single slides) |
FI 2822-1001-1 G FI 2822-1002-1 G FI 2822-1001-1 M * FI 2822-1002-1 M * |
Exanthema Profile 1 (consisting of 21 different substrates) |
IgG |
field A: verification BIOCHIP, HHV-6, Rubella virus*, Measles virus, Mumps virus |
10 x 01 (test system) 10 x 02 (test system) 10 x 01 (test system) 10 x 02 (test system) |
|
FI 2824-1001-1 G FI 2824-1002-1 G FI 2824-1001-1 M * FI 2824-1002-1 M * |
Central Nervous System Profile 1 (consisting of 21 different substrates) |
IgG IgM |
field A: verification BIOCHIP, Rubella virus*, Measles virus, Mumps virus, VZV |
10 x 01 (test system) 10 x 02 (test system) 10 x 01 (test system) 10 x 02 (test system) |
|
FI 2826-1001-1 G FI 2826-1002-1 G FI 2826-1001-1 M FI 2826-1002-1 M |
Infectious Arthritis Profile 1 (consisting of 13 different substrates) |
IgG IgM |
field A: verification BIOCHIP, VZV, Influenza virus type A (H1N1 and H3N2) and B field B: Yersinia enterocolitica O:3*, O:6*, O:9*, Toxoplasma gondii field C: Borrelia afzelii, burgdorferi (CH), garinii, Chlamydia trachomatis |
10 x 01 (test system) 10 x 02 (test system) 10 x 01 (test system) 10 x 02 (test system) |
|
CK 2650-0220-L G | CSQ pair of controls anti-VZV (IgG) |
IgG | 2 x 2 ml, ready for use | ||
CI 2650-0101 A | antibodies against Varicella zoster virus (VZV) IgA positive control |
IgA | 0.1 ml | ||
CI 2650-0101 Z | Varicella zoster virus (VZV) negative control |
IgA, IgG, IgM | 0.1.ml | ||
CI 2650-0101 G | antibodies against Varicella zoster virus (VZV) IgG positive control |
IgG | 0.1. ml | ||
CI 2650-0101 M | antibodies against Varicella zoster virus (VZV) IgM positive control |
IgM | 0.1 ml | ||
CI 2650-0101 H | high-avid antibodies against Varicella zoster virus (VZV) IgG positive control |
avidity test | 0.1 ml | ||
CI 2650-0101 X | low-avid antibodies against Varicella zoster virus (VZV) IgG positive control |
avidity test | 0.1 ml |
|
Antibody specificity / reagent / analyte |
Ig |
Substrate |
Species |
Format
|
EI 2650-9601 A |
Varicella zoster virus |
IgA |
|
semi-quantitative |
96 x 01 |
EI 2650-9601 G |
Varicella zoster virus (VZV) |
IgG |
10/100/500/5000 IU/I |
96 x 01 | |
EI 2650-9601 M | Varicella zoster virus (VZV) incl. IgG/RF absorbent |
IgM |
semi-quantitative |
96 x 01 | |
EI 2650-9601-1 G | Varicella zoster virus (VZV) avidity determination |
IgG |
10/100/500/5000 IU/I |
96 x 01 | |
EI 2650-9601-2 M | Varicella zoster virus (VZV) glycoprotein incl. IgG/RF absorbent |
IgM | semi-quantitative | 96 x 01 | |
EI 2650-9601-L A | Varicella zoster virus (VZV) antibody determination in CSF |
IgA | 5/25/50/100 U | 96 x 01 | |
EI 2650-9601-L G | Varicella zoster virus (VZV) antibody determination in CSF |
IgG | 5/25/50/100/175/230 U | 96 x 01 | |
DN 2410-1601-11 G DN 2410-6401-11 G |
"TO.R.C.H. 10" (Toxoplasma gondii, Rubella virus, CMV, HSV-1, HSV-2, Bordetella pertussis, Chlamydia trachomatis, Parvovirus B19, Treponema pallidum, VZV separately) |
IgG |
EUROLINE | 16 strips 64 strips |
|
FI 2650-1005 A FI 2650-1010 A FI 2650-1005 G FI 2650-1010 G FI 2650-1005 M FI 2650-1010 M FI 2650-1005 X FK 2650-1005 |
Varicella zoster virus (VZV |
IgA IgG IgM avidity test |
infected cells |
EU 168 |
10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system) 10 x 10 (test system) 10 x 05 (test system) 10 x 05 (single slides) |
FI 2822-1001-1 G FI 2822-1002-1 G FI 2822-1001-1 M * FI 2822-1002-1 M * |
Exanthema Profile 1 (consisting of 21 different substrates) |
IgG |
field A: verification BIOCHIP, HHV-6, Rubella virus*, Measles virus, Mumps virus |
10 x 01 (test system) 10 x 02 (test system) 10 x 01 (test system) 10 x 02 (test system) |
|
FI 2824-1001-1 G FI 2824-1002-1 G FI 2824-1001-1 M * FI 2824-1002-1 M * |
Central Nervous System Profile 1 (consisting of 21 different substrates) |
IgG IgM |
field A: verification BIOCHIP, Rubella virus*, Measles virus, Mumps virus, VZV |
10 x 01 (test system) 10 x 02 (test system) 10 x 01 (test system) 10 x 02 (test system) |
|
FI 2826-1001-1 G FI 2826-1002-1 G FI 2826-1001-1 M FI 2826-1002-1 M |
Infectious Arthritis Profile 1 (consisting of 13 different substrates) |
IgG IgM |
field A: verification BIOCHIP, VZV, Influenza virus type A (H1N1 and H3N2) and B field B: Yersinia enterocolitica O:3*, O:6*, O:9*, Toxoplasma gondii field C: Borrelia afzelii, burgdorferi (CH), garinii, Chlamydia trachomatis |
10 x 01 (test system) 10 x 02 (test system) 10 x 01 (test system) 10 x 02 (test system) |
|
CK 2650-0220-L G | CSQ pair of controls anti-VZV (IgG) |
IgG | 2 x 2 ml, ready for use | ||
CI 2650-0101 A | antibodies against Varicella zoster virus (VZV) IgA positive control |
IgA | 0.1 ml | ||
CI 2650-0101 Z | Varicella zoster virus (VZV) negative control |
IgA, IgG, IgM | 0.1.ml | ||
CI 2650-0101 G | antibodies against Varicella zoster virus (VZV) IgG positive control |
IgG | 0.1. ml | ||
CI 2650-0101 M | antibodies against Varicella zoster virus (VZV) IgM positive control |
IgM | 0.1 ml | ||
CI 2650-0101 H | high-avid antibodies against Varicella zoster virus (VZV) IgG positive control |
avidity test | 0.1 ml | ||
CI 2650-0101 X | low-avid antibodies against Varicella zoster virus (VZV) IgG positive control |
avidity test | 0.1 ml |